{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T04:10:48Z","timestamp":1776312648965,"version":"3.50.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,8,13]],"date-time":"2014-08-13T00:00:00Z","timestamp":1407888000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"published-print":{"date-parts":[[2014,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Gemcitabine\/Cisplatin (Gem\/CDDP) combination has demonstrated a clear survival advantage over gemcitabine alone and has become a new standard in advanced Biliary Tract Carcinoma (aBTC). However, Gemcitabine\/Oxaliplatin (GEMOX) combination and Gemcitabine\/Carboplatin (Gem\/Carb) combination regimens have shown efficacy in phase II trials and there is no comparative study between different platinum salts.<\/jats:p>\n            <jats:p>We assessed the efficacy and safety of different platinum-based chemotherapies at first line in aBTC patients. We also analysed the second-line chemotherapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Sixty-four consecutive patients with aBTC diagnosed between 1998 and 2010 were included for analysis. At first line chemotherapy, 44 patients received one day GEMOX regimen (gemcitabine 1000 mg\/m<jats:sup>2<\/jats:sup> and oxaliplatin 100 mg\/m<jats:sup>2<\/jats:sup> Day 1, every 2 weeks), and 20 patients received Gem\/Carb regimen (gemcitabine at 1000 mg\/m<jats:sup>2<\/jats:sup> Days 1 and 8 with carboplatin delivered according to an area-under-the-curve (AUC) 5 at day 1, every 3 weeks). At second line, a total of 16 patients received a fluoropyrimidine-based chemotherapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>With GEMOX regimen, median progression-free survival (PFS) was 3.7 months (95%CI, 2.4 to 5) and median overall survival (OS) was 10.5 months (95%CI, 6.4 to14.7). The main toxicity was peripheral neuropathy (20% grade 2 and 7% grade 3). Grade 3\/4 haematological toxicities were rare.<\/jats:p>\n            <jats:p>With Gem\/Carb regimen, PFS was 2.5 months (95%CI, 2.1 to 3.7) and OS was 4.8 months (95%CI, 3.7 to 5.8). The main grade 3\/4 toxicities were haematological: anaemia (45%), thrombocytopenia (45%), and neutropenia (40%).<\/jats:p>\n            <jats:p>At second-line, fluoropyrimidine-based chemotherapy was feasible in only a fourth of the patients. The median OS was 5.3\u00a0months (95%CI, 4.1 to 6.6), and median PFS was 4.0\u00a0months (95%CI, 2.6 to 5.5).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>One day GEMOX regimen has a favourable toxicity profile and could be an alternative to standard Gem\/CDDP regimen, in particular in unfit patients for CDDP.<\/jats:p>\n            <jats:p>At second-line, selective patients may benefit from fluoropyrimidine-based chemotherapy.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-230x-14-143","type":"journal-article","created":{"date-parts":[[2014,8,13]],"date-time":"2014-08-13T14:25:12Z","timestamp":1407939912000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Advanced biliary tract carcinomas: a retrospective multicenter analysis of first and second-line chemotherapy"],"prefix":"10.1186","volume":"14","author":[{"given":"Fr\u00e9d\u00e9ric","family":"Fiteni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marine","family":"Jary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franck","family":"Monnien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thierry","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Beohou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Demarchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erion","family":"Dobi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francine","family":"Fein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denis","family":"Cleau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serge","family":"Fratt\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginie","family":"Nerich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franck","family":"Bonnetain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Pivot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christophe","family":"Borg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,8,13]]},"reference":[{"key":"1175_CR1","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.dld.2010.05.002","volume":"43","author":"D Alvaro","year":"2011","unstructured":"Alvaro D, Bragazzi MC, Benedetti A, Fabris L, Fava G, Invernizzi P, Marzioni M, Nuzzo G, Strazzabosco M, Stroffolini T: Cholangiocarcinoma in Italy: A national survey on clinical characteristics, diagnostic modalities and treatment. Results from the \u201cCholangiocarcinoma\u201d committee of the Italian Association for the Study of Liver disease. Dig Liver Dis. 2011, 43: 60-65. 10.1016\/j.dld.2010.05.002.","journal-title":"Dig Liver Dis"},{"key":"1175_CR2","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1038\/sj.bjc.6603127","volume":"94","author":"J West","year":"2006","unstructured":"West J, Wood H, Logan RF, Quinn M, Aithal GP: Trends in the incidence of primary liver and biliary tract cancers in England and Wales 1971\u20132001. Br J Cancer. 2006, 94: 1751-1758. 10.1038\/sj.bjc.6603127.","journal-title":"Br J Cancer"},{"key":"1175_CR3","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1093\/oxfordjournals.annonc.a010676","volume":"7","author":"B Glimelius","year":"1996","unstructured":"Glimelius B, Hoffman K, Sjoden PO, Jacobsson G, Sellstrom H, Enander LK, Linne T, Svensson C: Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol. 1996, 7: 593-600. 10.1093\/oxfordjournals.annonc.a010676.","journal-title":"Ann Oncol"},{"key":"1175_CR4","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1038\/sj.bjc.6602576","volume":"92","author":"S Rao","year":"2005","unstructured":"Rao S, Cunningham D, Hawkins RE, Hill ME, Smith D, Daniel F, Ross PJ, Oates J, Norman AR: Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer. Br J Cancer. 2005, 92: 1650-1654. 10.1038\/sj.bjc.6602576.","journal-title":"Br J Cancer"},{"key":"1175_CR5","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1093\/annonc\/mdh096","volume":"15","author":"GV Kornek","year":"2004","unstructured":"Kornek GV, Schuell B, Laengle F, Gruenberger T, Penz M, Karall K, Depisch D, Lang F, Scheithauer W: Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial. Ann Oncol. 2004, 15: 478-483. 10.1093\/annonc\/mdh096.","journal-title":"Ann Oncol"},{"key":"1175_CR6","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.ejca.2004.10.026","volume":"41","author":"M Ducreux","year":"2005","unstructured":"Ducreux M, Van Cutsem E, Van Laethem JL, Gress TM, Jeziorski K, Rougier P, Wagener T, Anak O, Baron B, Nordlinger B: A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial. Eur J Cancer. 2005, 41: 398-403. 10.1016\/j.ejca.2004.10.026.","journal-title":"Eur J Cancer"},{"key":"1175_CR7","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1159\/000096249","volume":"70","author":"N Androulakis","year":"2006","unstructured":"Androulakis N, Aravantinos G, Syrigos K, Polyzos A, Ziras N, Tselepatiotis E, Samonis G, Kentepozidis N, Giassas S, Vamvakas L, Georgoulias V: Oxaliplatin as first-line treatment in inoperable biliary tract carcinoma: a multicentre phase II study. Oncology. 2006, 70: 280-284. 10.1159\/000096249.","journal-title":"Oncology"},{"key":"1175_CR8","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1038\/sj.bjc.6603648","volume":"96","author":"F Eckel","year":"2007","unstructured":"Eckel F, Schmid RM: Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer. 2007, 96: 896-902. 10.1038\/sj.bjc.6603648.","journal-title":"Br J Cancer"},{"key":"1175_CR9","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1038\/sj.bjc.6604628","volume":"99","author":"T Andr\u00e9","year":"2008","unstructured":"Andr\u00e9 T, Reyes-Vidal JM, Fartoux L, Ross P, Leslie M, Rosmorduc O, Clemens MR, Louvet C, Perez N, Mehmud F, Scheithauer W: Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study. Br J Cancer. 2008, 99: 862-867. 10.1038\/sj.bjc.6604628.","journal-title":"Br J Cancer"},{"key":"1175_CR10","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1038\/sj.bjc.6603334","volume":"95","author":"J Harder","year":"2006","unstructured":"Harder J, Riecken B, Kummer O, Lohrmann C, Otto F, Usadel H, Geissler M, Opitz O, Henss H: Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancer. Br J Cancer. 2006, 95: 848-852. 10.1038\/sj.bjc.6603334.","journal-title":"Br J Cancer"},{"key":"1175_CR11","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s00280-009-1055-0","volume":"65","author":"A Sharma","year":"2010","unstructured":"Sharma A, Mohanti B, Raina V, Shukla N, Pal S, Dwary A, Deo S, Sahni P, Garg P, Thulkar S, DattaGupta S, Rath G: A phase II study of gemcitabine and oxaliplatin (Oxigem) in unresectable gall bladder cancer. Cancer Chemother Pharmacol. 2010, 65: 497-502. 10.1007\/s00280-009-1055-0.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1175_CR12","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s00280-009-1069-7","volume":"65","author":"JS Jang","year":"2010","unstructured":"Jang JS, Lim HY, Hwang IG, Song HS, Yoo N, Yoon S, Kim YH, Park E, Byun JH, Lee MA, Oh SJ, Lee KH, Kim BS, Oh SC, Kim SY, Lee SJ: Gemcitabine and oxaliplatin in patients with unresectable biliary cancer including gall bladder cancer: a Korean Cancer Study Group phase II trial. Cancer Chemother Pharmacol. 2010, 65: 641-647. 10.1007\/s00280-009-1069-7.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1175_CR13","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J, ABC-02 Trial Investigators: Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010, 362: 1273-1281. 10.1056\/NEJMoa0908721.","journal-title":"N Engl J Med"},{"key":"1175_CR14","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s002800050955","volume":"44","author":"S Faivre","year":"1999","unstructured":"Faivre S, Raymond E, Woynarowski JM, Cvitkovic E: Supraadditive effect of 2\u2032, 2\u2032\u2013difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines. Cancer Chemother Pharmacol. 1999, 44: 117-123. 10.1007\/s002800050955.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1175_CR15","doi-asserted-by":"publisher","first-page":"4581","DOI":"10.1200\/JCO.2010.29.3605","volume":"28","author":"A Sharma","year":"2010","unstructured":"Sharma A, Dwary AD, Mohanti BK, Deo SV, Pal S, Sreenivas V, Raina V, Shukla NK, Thulkar S, Garg P, Chaudhary SP: Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study. J Clin Oncol. 2010, 28: 4581-4586. 10.1200\/JCO.2010.29.3605.","journal-title":"J Clin Oncol"},{"key":"1175_CR16","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/S0169-5002(03)00233-2","volume":"41","author":"P Zatloukal","year":"2003","unstructured":"Zatloukal P, Petruzelka L, Zemanov\u00e1 M, Kolek V, Skrickov\u00e1 J, Pesek M, Fojt\u016f H, Gryg\u00e1rkov\u00e1 I, Sixtov\u00e1 D, Roubec J, Horenkov\u00e1 E, Havel L, Pr\u016fsa P, Nov\u00e1kov\u00e1 L, Sk\u00e1cel T, K\u016fta M: Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIB and IV non-small cell lung cancer: A phase III randomized trial. Lung Cancer. 2003, 41: 321-331. 10.1016\/S0169-5002(03)00233-2.","journal-title":"Lung Cancer"},{"key":"1175_CR17","doi-asserted-by":"publisher","first-page":"8380","DOI":"10.1200\/JCO.2005.01.2781","volume":"23","author":"C Sederholm","year":"2005","unstructured":"Sederholm C, Hillerdal G, Lamberg K, K\u00f6lbeck K, Dufmats M, Westberg R, Gawande SR: Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: the Swedish Lung Cancer Study Group. J Clin Oncol. 2005, 23: 8380-8388. 10.1200\/JCO.2005.01.2781.","journal-title":"J Clin Oncol"},{"key":"1175_CR18","doi-asserted-by":"publisher","first-page":"5634","DOI":"10.1200\/JCO.2008.21.4924","volume":"27","author":"M De Santis","year":"2009","unstructured":"De Santis M, Bellmunt J, Mead G, Kerst JM, Leahy M, Maroto P, Skoneczna I, Marreaud S, de Wit R, Sylvester R: Randomized phase II\/III trial assessing gemcitabine\/carboplatin and methotrexate\/carboplatin\/vinblastine in patients with advanced urothelial cancer \u201cunfit\u201d for cisplatin-based chemotherapy: phase II--results of EORTC study 3098. J Clin Oncol. 2009, 27: 5634-5639. 10.1200\/JCO.2008.21.4924.","journal-title":"J Clin Oncol"},{"key":"1175_CR19","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1111\/j.1477-2574.2010.00197.x","volume":"12","author":"KJ Williams","year":"2010","unstructured":"Williams KJ, Picus J, Trinkhaus K, Fournier CC, Suresh R, James JS, Tan BR: Gemcitabine with carboplatin for advanced biliary tract cancers: a phase II single institution study. HPB (Oxford). 2010, 12: 418-426. 10.1111\/j.1477-2574.2010.00197.x.","journal-title":"HPB (Oxford)"},{"key":"1175_CR20","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/S1470-2045(14)70212-8","volume":"15","author":"D Malka","year":"2014","unstructured":"Malka D, Cervera P, Foulon S, Trarbach T, de la Fouchardi\u00e8re C, Boucher E, Fartoux L, Faivre S, Blanc JF, Viret F, Assenat E, Seufferlein T, Herrmann T, Grenier J, Hammel P, Dollinger M, Andr\u00e9 T, Hahn P, Heinemann V, Rousseau V, Ducreux M, Pignon JP, Wendum D, Rosmorduc O, Greten TF, BINGO investigators: Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial. Lancet Oncol. 2014, 15: 819-28. 10.1016\/S1470-2045(14)70212-8.","journal-title":"Lancet Oncol"},{"key":"1175_CR21","doi-asserted-by":"publisher","first-page":"s4","DOI":"10.1200\/JCO.2010.32.1752","volume":"29","author":"J Mane","year":"2011","unstructured":"Mane J, Iruarrizaga E, Rubio I, Fonseca E, Iza E, Casas R, Marrodan I, Martinez M, Fernandez R, Carrera S: Second-line chemotherapy with capecitabine (CAP) and oxaliplatin (OX) in patients with pancreatic or biliary tree adenocarcinoma (ADC). 2011 Gastrointestinal Cancers Symposium [abstract 308]. J Clin Oncol. 2011, 29: s4-10.1200\/JCO.2010.32.1752.","journal-title":"J Clin Oncol"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-230X-14-143.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-230X-14-143\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-230X-14-143","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-230X-14-143.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T05:32:19Z","timestamp":1630560739000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/1471-230X-14-143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,13]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["1175"],"URL":"https:\/\/doi.org\/10.1186\/1471-230x-14-143","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,13]]},"assertion":[{"value":"9 August 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"143"}}